Mini-Organs grown in Switzerland are Here to Change Drug Discovery

Screenshot 2016 12 16 at 10.46.56 AM 1 e1481881804814

This week we travel to Lausanne, a thriving biotech hub in Switzerland. Here, QGel is working to replicate the complexity of life in vitro in lab-grown mini-organs to improve drug discovery. Cool, right?

qgel logo

City: Lausanne, Switzerland

Founded: 2009

Employees: 11-50

Financial data: Total of €12M raised (12/2016)


Colin Sanctuary QGel
Colin Sanctuary, co-founder and CEO

Mission: QGel creates personalized arrays that can mimic the cellular architecture of different organs. As a result, these models can be used to better predict how a drug will affect the human body and save time and money in the process of drug discovery.


Comment: Apart from specific organ diseases, QGel can replicate the tumor microenvironment in vitro to help the development of novel cancer drugs. One of its key focus is mimicking the extracellular matrix (ECM) surrounding the cells, which is being increasingly recognized in research as an essential factor controlling cellular behavior.

P.S. I personally love the illustrations on its website!

QGel Technology

Featured image: Labiotech map; figure from QGel

Explore other topics: CancerDrug discoverySwitzerland

Newsletter Signup - Under Article / In Page

"*" indicates required fields

Subscribe to our newsletter to get the latest biotech news!

This field is for validation purposes and should be left unchanged.